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Available online 3 June 2016Generating human podocytes in vitro could offer a unique opportunity to study human diseases. Here, we de-
scribe a simple and efﬁcient protocol for obtaining functional podocytes in vitro from human induced pluripotent
stem cells. Cells were exposed to a three-step protocol, which induced their differentiation into intermediateme-
soderm, then into nephron progenitors and, ﬁnally, into mature podocytes. After differentiation, cells expressed
themain podocytemarkers, such as synaptopodin, WT1,α-Actinin-4, P-cadherin and nephrin at the protein and
mRNA level, and showed the low proliferation rate typical of mature podocytes. Exposure to Angiotensin II sig-
niﬁcantly decreased the expression of podocyte genes and cells underwent cytoskeleton rearrangement. Cells
were able to internalize albumin and self-assembled into chimeric 3D structures in combinationwith dissociated
embryonic mouse kidney cells. Overall, these ﬁndings demonstrate the establishment of a robust protocol that,
mimicking developmental stages, makes it possible to derive functional podocytes in vitro.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Podocytes1. Introduction
Podocytes are terminally differentiated epithelial cells that have lim-
ited capacity to proliferate. This feature makes them vulnerable to crit-
ical levels of cell stress leading to detachment and progressive cell
loss, a central mediator of glomerular sclerosis. Over the last decade, in-
vestigators have attempted to understand why podocyte depletion per
se is sufﬁcient to cause glomerulosclerosis, and to identify themediators
responsible for local propagation of podocyte injury. In this context, the
possibility of having podocyte cultureswould be a valuable tool for clar-
ifying the molecular mechanisms underlying speciﬁc podocytopathies
with a view to developing targeted therapy.
First attempts to derive primary podocytes from isolated glomeruli
failed largely because podocytes cultured under standard conditions de-
differentiate rapidly, with a loss of foot processes and expression of
synaptopodin, a key marker of differentiated podocytes. Changes ine Farmacologiche Mario Negri,
Kilometro Rosso, Via Stezzano,
ni).
icines & Early Development
1, SE-43183Mölndal, Sweden.
. This is an open access article underculture conditions resulted in cells with the characteristic arborized
phenotype and rapid growth arrest, and the latter closely reﬂected in
vivo podocyte behaviour, but limited cell culture abilities for in vitro ex-
periments (Shankland et al., 2007). The establishment of conditionally
immortalized cell lines circumvented the detrimental cell growth arrest,
generating highly proliferative cells under permissive conditions, which
stopped growing in non-permissive conditions. However, despite their
widespread use for studying podocyte biology, these cell lines show
dramatic differences in the expression of podocyte markers, response
to toxins, and motility, not only between podocytes of different species
but even between similarly-derived cell lines (Chittiprol et al., 2011).
A potentially exciting possibility for deriving podocytes has been
created by studies by Romagnani and co-workers, who identiﬁed and
isolated renal progenitor cells (RPCs) from the parietal epithelium of
Bowman's capsule of the adult kidney (Ronconi et al., 2009). This
CD133+CD24+ cell population, which represents 1 to 4% of all renal
cells, exhibits heterogeneous potential for differentiation into different
renal cells. In this cell population, the subset of CD133+CD24+-
Podocalyxin− cells displayed the potential to differentiate into podocytes
and tubular cells in vitro and to functionally improve glomerular and
tubulointerstitial injury in a model of adriamycin-induced renal injury.
Despite promising results, difﬁculties with accessing human RPCs from
kidney biopsies has pushed research towards searching for a new sourcethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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urine itself may represent a possible source of renal progenitor cells. To
this end, the same group (Lazzeri et al., 2015) did establish RPC cultures
from the urine of children with glomerular genetic disorders with the
aim of obtaining podocytes and tubular cells. However, the major limita-
tion of this technique is that the success rate for achieving a culture ranges
from8% to 51%, according to the phase of the disease, anddrops to 0%with
healthy subjects (Lazzeri et al., 2015).
The breakthrough discovery of induced pluripotent stem cells
(iPSCs)makes it possible to generate cells in vitrowith an overall genet-
ic and epigenetic background identical to donor cells, making iPSCs the
ideal tool for in vitro disease modelling (Ye et al., 2013). The derivation
of podocytes from pluripotent stem cells is an attractive alternative and
an inexhaustible source of podocytes. Recently, different protocols for
iPSC commitment towards renal progenitor cells through the activation
of Wnt, bone morphogenic protein (BMP), ﬁbroblast growth factor
(FGF) and retinoic acid (RA) pathways involved in the induction of the
intermediate mesoderm (IM) and subsequently in the metanephric
mesenchyme and ureteric bud cells have been reported (Batchelder
et al., 2009; Imberti et al., 2015; Kim and Dressler, 2005; Mae et al.,
2010; Mae et al., 2013; Oeda et al., 2013; Taguchi et al., 2014;
Takasato et al., 2014; Xia et al., 2013). The feasibility of deriving more
mature kidney cells from pluripotent stem cells has also been demon-
strated (Kang and Han, 2014; Kobayashi et al., 2005; Lam et al., 2014;
Song et al., 2012).
Here, we propose a simple and robust three-stage protocol based on
single cell differentiation in chemically deﬁned and feeder-free condi-
tions, allowing for the highly efﬁcient generation of human iPSC-de-
rived podocytes. The podocytes generated are mature cells expressing
the main podocyte markers and are able to respond to Angiotensin II,
one of the major players in podocyte injury, and to internalize BSA
and to integrate intoWT1 positive structures in an ex-vivomodel of de-
veloping kidney.
2. Materials and methods
2.1. Human iPSC culture
The human Episomal iPS cell line from Life Technologies (Grand Is-
land, NY), hiPSC Clone IV and hiPSC#16 cell lines generated in our labo-
ratories were cultured on hESC-qualiﬁedmatrigel (BD Biosciences, New
Jersey, USA) coated dishes in mTeSR1 medium (StemCell Technologies,
Vancouver, Canada). Cells were routinely sub-cultured using Accutase
(Life Technologies) and plated twice a week as small clumps at a dilu-
tion of 1:10 to 1:15.
2.2. Human iPSC differentiation into podocytes
For differentiation, hiPSCs were dissociated using Accutase and plat-
ed on growth factor reduced matrigel (BD Biosciences) coated dishes at
a density of 30,000/50,000 cells/cm2 in mTeSR1 medium with 10 μM
ROCK inhibitor Y-27632 (Sigma, Milan, Italy). After one day medium
was replaced with a medium consisting of a 1:1 mixture of
DMEM:F12 (1:1) plus Glutamax (Life Technologies) and neurobasal
media with N2 and B27 supplements (all Life Technologies, N2B27me-
dium), in the presence of 1 μM CP21R7 (Roche) and 25 ng/ml BMP4
(Prepotech, USA). The ﬁrst induction medium was maintained for
three days and thereafter replaced with STEMdiff APEL medium
(StemCell Technologies) supplemented with 100 nM Retinoic Acid
(Sigma), 50 ng/ml BMP7 (Prepotech) and 200 ng/ml FGF9 (Abnova, Tai-
pei City, Taiwan) for 2 more days. On day 6 of differentiation, cells were
dissociated with Accutase and plated on type I collagen-coated plates at
a density of 20,000/40,000 cells/cm2 and cultured for 7 days in VRAD
medium consisting of DMEM:F12 plus Glutamax (Life Technologies)
supplemented with 10% FBS, Retinoic Acid (80–100 μM depending on
the cell line) and 100 nM Vitamin D3.2.3. Derivation and characterization of human iPSC#16
2.3.1. Generation of human iPS cell line
Human iPSCswere derived fromperipheral bloodmononuclear cells
(PBMCs) through Sendai virus-mediated reprogramming using
CytoTune- iPS 2.0 Sendai reprogrammingKit (Life Technologies) follow-
ing manufacturer's instruction. PBMCs were isolated from healthy
donor by Ficoll-Plaque gradient. Brieﬂy, PBMCs were thawed four days
before infection and cultured in StemPro-34 medium (Life Technolo-
gies) supplemented with cytokines (PBMC medium). The day of infec-
tion around 300,000 PBMCs were infected with 5 MOI hKOS, 5 MOI
hc-Myc and 3 MOI hKLF4 Sendai virus. Three days after the infection
the cells were plated at different densities on MEF-feeder coated dishes
(e.g. from 10,000 to 50,000 per well of six well-plate) and cultured in
PBMC medium without cytokines for other four days, replacing spent
medium every other day. On day seven post-infection the PBMC medi-
umwas replacedwith human iPSC-medium (DMEMF12, 20%KO serum,
0.1 mM NEAA, 0.1 mM 2-mercaptoethanol and 10 ng/ml bFGF). The
iPSC-medium was changed every other day until the ﬁrst colonies
started to appear, and then every day. iPSC colonies were manually
picked about 20 days post-infection, transferred into 0.5 ml of human
iPSC-medium and dissected to small clumps by pipetting and seeded
onto a new MEFs feeder in a well of six well-plate. The colonies were
mechanically split for 4 passages and then adapted to growth on hESC
qualiﬁed- matrigel (BD Biosciences) in mTeSR1 medium and cultured
as described above. hiPSC#16 clone has been chosen for characteriza-
tion by conventional methods (immunostaining and qRT-PCR for
pluripotency marker expression, karyotype analysis and embryoid
body formation) and for differentiation studies.2.3.2. Karyotyping
Metaphase spreads were prepared after treatment with 10 mg/ml
Colcemid and processed for karyotype analysis. At least 20 metaphases
of each sample were counted. Karyotype analysis was performed in col-
laborationwith theGeneticMedicine Laboratory of AziendaOspedaliera
Papa Giovanni XXIII, Bergamo (Italy).2.3.3. Embryoid body (EB) formation
For EB formation, human iPSC#16 cells were harvested after
Accutase detachment and counted by Trypan Blue solution. Around
106 live cells were plated in each well of AggreWell 800 plate (Stem
Cell Technologies) in AggreWell medium (Stem Cell Technologies)
plus 10 μM ROCK inhibitor (Sigma). Forty-eight hours after plating,
EBs were transferred into Ultra Low-attach six well-plate (Corning,
USA) and the medium was replaced every other day. After 8 days as
ﬂoating culture, EBswere transferred onto gelatin-coated plate and cul-
tured in the samemedium for another 8 days. On day sixteen the plates
were ﬁxed with 4% PFA solution and processed by immunostaining.2.4. Immunocytochemistry
The cells were ﬁxed with PBS containing 4% paraformaldehyde for
15 min at room temperature. After three washes with PBS, the cells
were permeabilized with 0.3% Triton for 15 min at room temperature
(when necessary) and then incubated for 1 h with 5% BSA as a blocking
solution. For synaptopodin staining, the cells were ﬁxed with 1:1 mix-
ture of EtOH/Acetone for 10 min at 4 °C. The samples were stained
with the primary antibody diluted in 2% BSA solution overnight at 4 °
C, followed by incubation with the appropriate secondary antibody for
1 h at room temperature. Nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI) for 5 min at RT. Images were taken
using CF40 Axiovert ﬂuorescence microscope (Zeiss, Oberkochen, Ger-
many) and are representative of n = 3 experiments. The primary and
secondary antibodies used are listed in Supplementary Table S1.
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Total RNA was isolated with Trizol (Life Technologies) and treated
with DNAse (Promega) as described by the manufacturer. 2.5 μg of
total RNA were used for reverse transcription reaction with Superscript
II kit (Life Technologies) following the manufacturer's instructions.
Quantitative real-time PCR assays were performed using Taqman gene
expression assays (Life Technologies) using predesigned Taqman probes
for the genes of interest according to the supplier's recommendations
(Supplementary Table S2) and gene expression levels were normalized
to the housekeeping gene HPRT1. To amplify cDNA of SIX2, CD2AP
and ACTN4, SYBR Green PCR Master Mix (Applied Biosystems, Life
Technologies) according to themanufacturer's protocol and the following
primers (300 nM) were used: human SIX2 forward 5′-CTTGCCA-
CCGTTCATTCT-3′ and reverse 5′-GGACCAGGACACAGAGTA-3′; human
CD2AP forward 5′-CCCTGGATGAACTTAGAGCCC-3′ and reverse 5′-
TCCAGTTCTTTCCCGTGATCC-3′; human ACTN4 forward 5′-GAGCAAG-
CAGCAGTCCAAC-3′, and reverse 5′-GCCCGATCTCCTCCATCTTG-3′;
human HPRT forward 5′-GGCAGTATAATCCAAAGATGGTCA-3′, and re-
verse 5′-TCCTTTTCACCAGCAAGCTTG-3′.
2.6. Scanning electron microscopy analysis
For scanning electron microscopy analysis, nephron progenitor cells
obtained on day 6 of the differentiation protocol (n = 2) were seeded
on collagen Type I coated Thermanox slides (Thermo Fisher Scientiﬁc,
USA) and cultured in the podocyte-differentiating medium VRAD
for seven days. After differentiation, cells were ﬁxed in 2.5% glutaralde-
hyde (buffered with 0.1 M sodium cacodylate buffer, pH of 7.4) for 1 h,
post-ﬁxed in 1% osmium tetroxide, and dehydrated through an increasing
ethanol series. Cell monolayers were then dried with pure
hexamethyldisilazane (Sigma) (twice for 30 min), sputter-coated with
gold, and observed at scanning electronmicroscopy (Supra 55; Carl Zeiss).
2.7. Cell proliferation assay
On day 6 of the differentiation protocol cells were seeded in each
well of a 96-well plate in the presence (differentiated cells) or in the ab-
sence (undifferentiated cells) of VRAD medium at a cell density of
30,000 cells/cm2. Cells were then ﬁxed and stained with crystal violet
solution (Sigma) on days 7, 11 and 13 of the differentiation protocol,
rinsed, and then air-dried. The stain was eluted with an ethanol: 0.1 M
sodium citrate (1:1) solution, and absorbance at 595 nmwasmeasured.
The experiments (n = 3) were performed in triplicate and data are
expressed as mean ± s.e.m.
2.8. Cytoskeleton rearrangement evaluation
Human iPSC-derived podocytes were exposed to 100 nM and
500 nM Angiotensin II for 15 and 24 h in serum-free conditions. The
cells were then ﬁxedwith a 4% PFA solution for 15min at RT and stained
with rhodaminephalloidin (Molecular Probes, USA) for 1 h at RT follow-
ed by DAPI staining. For each condition an average of 10 ﬁelds (around
100 cells) were counted in three different experiments. The results are
expressed as the percentage of cells that showed cytoskeleton rear-
rangement compared to the total number of counted cells and are re-
ported as mean ± s.e.m.
2.9. Albumin uptake assay
An albumin uptake assay was performed as previously described
(Xinaris et al., 2015). Human iPSC-derived podocytes were incubated
with serum-free medium overnight. After washing with Ringer's buffer
pH 7.4, cells were exposed to 50 μg/ml FITC-conjugated bovine serum
albumin (BSA; Sigma-Aldrich) for 90 min at 37 °C. After washing with
Ringer's buffer, cells were ﬁxed in 4% PFA for 10 min at roomtemperature. Nuclei were stained with DAPI. Cells were mounted
using Dako Fluorescence Mounting Medium (DAKO) and examined by
ﬂuorescence microscope (ApoTome Axio Imager Z2, Zeiss).
2.10. Chimeric organoid cultures
Chimeric organoidswere constructed and cultured as previously de-
scribed (Xinaris et al., 2015). Brieﬂy, embryonic day (E) 12.5 CD1mouse
(Charles River Italia SpA) kidneys were dissected in MEM (M5650;
Sigma-Aldrich, St. Louis, MO), placed in 1× trypsin/EDTA (Biochrom
AG) for 5 min at 37 °C, and dissociated into single cell suspensions by
trituration and then ﬁltration through a 40 μm cell strainer (BD Falcon).
A total of 1.2 × 105mouse cells weremixedwith 1.2 × 104 human iPSC-
derived podocytes or undifferentiated iPSC (10:1, mouse:human) and
centrifuged at 900 ×g for 5 min. The resulting pellets were placed on
top of the 5 μm ﬁlter (Merck Millipore Ltd) supported by a metal grid
in a humidiﬁed atmosphere with 5% CO2 at 37 °C. Chimeric organoids
were cultured in Advanced DMEM (12494; Gibco, Invitrogen Corpora-
tion) supplemented with 2% Embryonic Stem cells Fetal Bovine Serum
(ES-FBS, Gibco), 1% L-glutamine (Invitrogen Corporation) and 1% peni-
cillin/streptomycin (Invitrogen). For the ﬁrst 24 hour organoids were
cultured in the presence of 1.25 μM Glycyl-H1152 dihydrochloride
(Tocris), a ROCK inhibitor.
2.11. Immunoﬂuorescence analysis of chimeric organoids
After 2 days of in vitro culture, chimeric organoids were ﬁxed in 4%
PFA for 10 min, permeabilized with 100% cold methanol for 10 min,
and incubated with mouse anti-E-cadherin (1:100, BD Biosciences),
rabbit anti-WT1 (1:50, Santa Cruz Biotechnology) followed by species-
speciﬁc secondary antibodies (1:50; Jackson ImmunoResearch Labora-
tories). To detect human cells, chimeric organoids were incubated
with FITC-conjugated anti–Human Nuclear Antigen (HNA, 1:100;
Merck Millipore Ltd). Chimeric organoids were mounted with Dako
Fluorescence Mounting Medium (DAKO Corporation) and examined
using an inverted confocal laser-scanning microscope (LS 510 Meta;
Carl Zeiss). 3D images of chimeric organoids were reconstructed using
the Axio Vision Imager software (Carl Zeiss).
2.12. Statistical analysis
Statistical analysis was performed using GraphPad Prism software
(version 6). Data were analyzed using ANOVA followed by the
Bonferroni test for multiple comparisons or t test for unpaired data, as
appropriate. P b 0.05was considered a statistically signiﬁcant difference.
3. Results
A highly efﬁcient and chemically deﬁned protocol for differentiating
human iPS cells into fully mature podocytes was attempted by trying to
recapitulate kidney developmental stages in vitro. The differentiation
protocol is based on three different stages, which include the induction
phase into intermediatemesoderm, commitment towards nephronpre-
cursors, and speciﬁcation into podocytes (Fig. 1A).
3.1. hiPSC commitment towards intermediatemesoderm (IM) and nephron
progenitor cells
Wnt/β-Catenin and BMP pathways have been reported to direct the
differentiation of human PSCs into mesoderm and IM-like precursors
(Mae et al., 2013; Sumi et al., 2008; Woll et al., 2008). Here we used a
new, potent, and highly selective GSK3β inhibitor as aWnt pathway ac-
tivator, to allow efﬁcient commitment of PSCs towards a mesodermal
fate. A complete characterization, in terms of Wnt signalling activation,
of the novel compound 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-
yl)-pyrrole-2,5-dione, referred to as CP21R7 (structure shown in Fig.
Fig. 1.Human iPSC induction towardsmesodermby the newly identiﬁedGSK3β inhibitor CP21R7. (A)Outline of the three-step differentiation protocol to obtain hiPSC-derivedpodocytes;
(B) CP21R7 chemical structure; (C) immunoﬂuorescence analysis of BRY and OCT4 displaying commitment to mesodermal fate and reduction of pluripotency. Scale bar 50 μm; (D) gene
expression analysis conﬁrmed the induction towards mesoderm through an increase in T (BRY) expression and the loss of pluripotency through a decrease inNANOG expression. Data are
expressed as mean ± s.e.m.
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tably, the TCF/LEF reporter assay in the human reporter cell line
(DeAlmeida et al., 2007) showed that CP21R7was able to potently acti-
vate canonical Wnt signalling even at the dose of 1 μM, with highest ac-
tivity seen at 3 μM. Moreover, the induction into mesoderm by the
combination of CP21R7 with bone morphogenic protein-4 (BMP4)
was also demonstrated (Patsch et al., 2015). On the basis of these re-
sults, 24 h after plating as a single-cell monolayer, commercially avail-
able human iPSCs were exposed to N2B27 medium, supplemented
with 1 μM GSK3β inhibitor CP21R7 and 25 ng/ml BMP4 for 3 days.
The expression of T (also known as Brachyury, T/BRY), a meso-endo-
derm marker expressed in the primitive streak, was evaluated during
the ﬁrst stage. Its expression was strongly upregulated by day 2 and
remained high until day 4 of differentiation. The concomitant loss of ex-
pression of the typical pluripotency markers was highlighted by a pro-
gressive decrease in NANOG and OCT4 at the mRNA and protein levels,
respectively (Fig. 1C, D). Previous studies investigating renal differenti-
ation of pluripotent cells have relied on PAX2, OSR1, and LHX1 as deﬁn-
itive markers for IM formation (James et al., 2006; Mae et al., 2013;
Torres et al., 1995; Tsang et al., 2000). According to this evidence, we
analyzed their expression both at the genomic and protein levels.
PAX2, OSR1, and LHX1 gene expression had already increased by day 2
of differentiation, reaching peak expression on day 3 (Fig. 2A). PAX2and OSR1 expression remained high until day 4, while LHX1 expression
decreased to control value (Fig. 2A). Cellular co-localization of OSR1 and
LHX1 as well as OSR1 and PAX2 protein, was observed from day 2 until
day 4 of the differentiation protocol, conﬁrming the induction of IM-like
cells (Fig. 2B).
To determine whether hiPSC-derived IM cells have the capacity to
give rise to more differentiated cells, IM-like cells were exposed to ﬁve
different combinations of cell culture media and growth factors, includ-
ing retinoic acid (RA), bone morphogenic protein-7 (BMP7) and ﬁbro-
blast growth factor-9 (FGF9), as depicted in Fig. 3A. RA and BMP7
have previously been described as inducing renal lineage from mESCs
(Kim and Dressler, 2005), and FGF9 can maintain nephron progenitors
in vitro (Barak et al., 2012). IM-like cells were exposed to stage II differ-
entiationmedia for 2 days and the induction of the expression of SIX2, a
key marker of nephron progenitor cells giving rise to podocytes, was
evaluated to deﬁne the best combination able to promote IM-like cell
maturation into renal progenitors. As shown by gene expression analy-
sis, combinations C, D and Ewere themost efﬁcient in inducing SIX2 ex-
pression (Fig. 3B). In particular, in combination D SIX2 expression on
day 6 was around nine-fold higher than that detected on day 4.
Prolonged exposure to the differentiation media failed to further in-
crease SIX2 expression, which was already downregulated by day 7 in
all the conditions tested (data not shown).
Fig. 2. Human iPSC speciﬁcation into intermediate mesoderm cells. (A) Gene expression analysis of PAX2, OSR1 and LHX1. Data are expressed as mean ± s.e.m.; (B) representative
immunoﬂuorescence images of co-staining for OSR1/LHX1 and OSR1/PAX2 up to day 4. Scale bar 50 μm.
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tity of cells generated in this speciﬁc combination, the expression of
markers speciﬁc to the nephron progenitor cells, such as PAX2 and
WT1, was also evaluated. Although PAX2 gene expression peaked in
the ﬁrst stage of differentiation between days 3 and 4 (Fig. 2A and Sup-
plementary Fig. S2B), immunoﬂuorescence analysis performed on cells
on day 6 of differentiation showed the presence of cells that co-
expressed SIX2 and PAX2 proteins (Fig. 3C and Supplementary Fig.
S3A). As occurs in normal kidney development (Armstrong et al.,
1993), at this stage of differentiation the expression of WT1 was still
weak both at the gene (Fig. 4D and Supplementary Fig. S3C) and protein
level (Fig. 3C and Supplementary Fig. S3A).
Given the use of N2B27 medium in neural differentiation, cells at
days 4 and 6 were analyzed by real-time PCR for the expression of
PAX6, a speciﬁc neural progenitormarker. Compared to undifferentiated
iPSCs, PAX6 expression dropped to undetectable levels in differentiated
cells (data not shown).
Taken together these results demonstrate that combination D could
efﬁciently induce the maturation of IM-like cells into nephron progeni-
tor-like cells, and we used this condition for the following step to pro-
mote nephron progenitor differentiation towards a podocyte lineage.
3.2. Speciﬁcation of hiPSC-derived nephron progenitor cells into podocytes
To obtain a podocyte-like phenotype, on day 6 of differentiation cells
were split, seeded on collagen type I-coated plates and cultured for
seven days in VRAD medium consisting of DMEM:F12 medium supple-
mentedwith 10% FBS, 100 nMof Vitamin D3 and 100 μMRA. VRADme-
dium has been reported to induce the differentiation of renal
progenitors isolated from the Bowman's capsule and from urine into
podocytes (Lazzeri et al., 2015; Ronconi et al., 2009).
On day 13 of differentiation, a homogeneous cell populationwithmul-
tinucleated cells characterized by a large cell body and arborizedmorphology was observed at light microscopy (Fig. 4A, top). To further
evaluate the ultrastructure of our iPSC-derived podocytes, we performed
scanning electronmicroscopy,which conﬁrmed the typical arborizedphe-
notype consisting of a main body surrounded by elongated processes re-
sembling foot processes (Fig. 4A, bottom). As human primary podocytes,
our iPSC-derived podocytes showed a low proliferation rate, as measured
through the proliferation assay performed on days 7, 11 and 13 of differ-
entiation. As shown in Fig. 4B, differentiated cells showed a growth arrest
from days 7 to 13 when compared to undifferentiated cells, conﬁrming
that iPSC-derived podocytes behaved like mature podocytes.
In addition to conﬁrming morphology and growth behaviour, we
also studied gene and protein expression of podocyte-speciﬁc markers.
After VRAD exposure, hiPSC-derived podocytes expressed several
podocyte proteins, such as the nuclear marker WT1 and the actin-bind-
ing and cross-linking protein α-Actinin-4. WT1 and α-Actinin-4 co-lo-
calization showed that more than 90% of cells expressed both markers
(Fig. 4C). Moreover, hiPSC-derived podocytes expressed the podocyte-
speciﬁc protein synaptopodin in a ﬁlamentous arrangement typical of
human podocytes. The expression of slit diaphragm protein P-cadherin
and nephrin was also evaluated, and the staining displayed typical pe-
ripheral cellular localization. The strong induction of podocyte markers
was also conﬁrmedby gene expression analysis. As shown in Fig. 4D, the
expression of ACTN4, SYNPO, CD2AP and NPSH1, was already upregulat-
ed by day 6, and further increased on day 13.WT1 expressionwas signif-
icantly upregulated on day 13. Notably, hiPSC-derived podocytes
expressed higher levels of VEGF-AmRNA compared to nephron progen-
itors at day 6 of differentiation.
3.3. Reproducibility and robustness of the protocol across different human
iPS cell lines
To evaluate the reproducibility and robustness of the protocol, the
differentiation was tested on other hiPSC lines that we generated
Fig. 3. Intermediate mesoderm cell commitment into nephron progenitors. (A) Schematic representation of the ﬁve conditions tested for inducing SIX2 expression; (B) SIX2 gene
expression analysis showed condition D as the most efﬁcient for inducing SIX2. Data are expressed as mean ± s.e.m.; (C) representative immunoﬂuorescence images of co-staining for
SIX2/PAX2 and WT1 expression on day 6 of condition D. Scale bar 50 μm.
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sources. The ﬁrst one, hiPSC Clone IV, was generated by STEMCCA lenti-
virus from human neonatal dermal ﬁbroblasts, and its pluripotency
properties had previously been demonstrated (Imberti et al., 2015).
The second iPS cell line, hiPSC#16, was on the other hand generated
by Sendai virus starting from human peripheral blood mononuclear
cells (PBMCs). As shown in Supplementary Fig. S1, the hiPSC#16 cell
line showed all the properties typical of pluripotent stem cells in
terms of pluripotency marker expression, at the protein and mRNA
level, the ability to differentiate in vitro into derivatives of the three
germ layers, and had a normal karyotype.
Both hiPSC lines showed a pattern of protein and gene expression
similar to that observed with the commercial iPSCs in all three stages
of the differentiation protocol. Indeed, downregulation of the
pluripotencymarkerOCT4was observed, going from the undifferentiat-
ed state to day 4 of differentiation. Conversely, upregulation of markers
speciﬁc to the mesoderm Brachyury and for the IM, such as OSR1,
LHX1and PAX2 (Supplementary Fig. S2A), was detected during the
ﬁrst stage of differentiation. In parallel, gene expression analysis of
pluripotency and IM markers conﬁrmed strong induction towards the
intermediate mesodermal fate (Supplementary Fig. S2B). The co-locali-
zation of SIX2 with PAX2 and WT1 identiﬁed nephron progenitor cells
on day 6 of differentiation, generated using combinationD (Supplemen-
tary Fig. S3A). Finally, speciﬁcation into podocytes was evaluated.
hiPSC-derived podocytes from both cell lines expressed the main
podocyte markers, WT1, α-Actinin-4, synaptopodin, P-cadherin and
the tight-junction protein ZO-1, at the protein andmRNA level (Supple-
mentary Fig. S3B, C) with efﬁciency estimated around 90% on the basis
of WT1 and α-Actinin-4 co-localization.Collectively, these results demonstrate that the protocol we
established supports the efﬁcient commitment of three different
human iPSC lines towards podocytes and provides the basis for func-
tional studies.
3.4. Functional traits of hiPSC-derived podocytes
In order to test whether iPSC-derived podocytes possessed function-
al properties, cells were exposed to Angiotensin II (Ang II), one of the
major players in podocyte injury, and the cytoskeleton rearrangement
and expression of podocytemarkerswere evaluated. To assess the cyto-
skeleton rearrangement, cells were exposed to two different concentra-
tions of Ang II (100 nM and 500 nM) for 15 and 24 h. Exposure of the
cells to Ang II treatment induced signiﬁcant reorganization of the F-
actin containing ﬁlaments. The pattern changed into reorganization of
F-actin to the cell periphery at the expense of trans-cytoplasmic micro-
ﬁlaments with retraction of foot processes, which compacted the cell
body (Fig. 5A). Notably, the Ang II effect on the F-actin arrangement
was dose- and time-dependent, with a higher percentage of cytoskele-
tal rearrangement (33%± 4.6) found 24 h after exposure to the highest
dose of Ang II (Fig. 5B). Moreover, these morphological changes were
associated with signiﬁcantly reduced expression of podocyte-speciﬁc
markers such as SYNPO,WT1, NPSH1 and ACTN4, evaluated 3 h after ex-
posure to 500 nMAng II (Fig. 5C). It is known that podocytes are able to
endocytose albumin (Eyre et al., 2007; Xinaris et al., 2015). To conﬁrm
this ability in our iPSC-derived podocytes, uptake of FITC-albumin was
examined by ﬂuorescencemicroscopy (Fig. 5D). After 90min of incuba-
tion, FITC-albumin was detected in abundant large vesicles within the
podocyte cell bodies near the perinuclear region.
Fig. 4. Podocyte speciﬁcation. (A) Representative images of hiPSC-derived podocytes visualized by light microscopy (top, scale bar: 20 μm) or by scanning electron microscopy (bottom,
scale bar: 10 μm); (B) proliferation assay showed no proliferation properties of hiPSC-derived podocytes during podocyte speciﬁcation step as compared to cells not exposed to VRAD
medium (undifferentiated cells). Data are expressed as mean ± s.e.m.; (C) immunostaining of the main podocyte markers. Scale bar: 20 μm; (D) gene expression analysis conﬁrmed
podocyte marker expression. Data are expressed as mean ± s.e.m.
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developing kidney tissue, human podocytes at 13 days of differentiation
were re-aggregatedwith fully dissociated E12.5mouse kidneys (Xinaris
et al., 2015), and cultured as explants for 2 days. Human iPSC-derived
podocytes were homogenously integrated into re-aggregated kidney
tissue to form ﬁne-grained chimeric organoids without having a disrup-
tive effect on renal development (Fig. 5E). Remarkably, human cells
were found abundantly in WT1-positive/E-cadherin-negative struc-
tures and co-expressed WT1 (Fig. 5F). Such integration did not occur
in re-aggregation experiments performed with undifferentiated iPSCs
that, on the contrary, were exclusively found in E-cadherin-positive
Ureteric Bud epithelia (Supplementary Fig. S4).
4. Discussion
From the developmental perspective, the kidney is a mesodermal
organ derived from the embryonic metanephros, which is composed
of the ureteric bud, whose maturation produces the collecting ducts,
the renal pelvis and ureters, and the intermediate mesoderm-derived
metanephric mesenchyme, from which renal tubules and glomeruli
originate. Over the last decade, a number of groups worldwide have
tested the feasibility of deriving renal cells from embryonic stem cells
or iPSCs. However, most of them generated mixed populations of pro-
genitor cells committed to the ureteric bud or metanephric mesen-
chyme fate. So far, few studies have demonstrated the ability of
progenitor cells to differentiate into more mature renal cells.
Kobayashi et al. (2005), and more recently Lam et al. (2014), promoted
stem cell differentiation into renal tubular cells. Two groups haveattempted to derive podocytes from hiPSCs, but both studies have
some limitations. Kang and Han described the generation of podocytes
as just the ability of nephron progenitors to differentiate into more ma-
ture cells without giving any evidence of podocyte functionality (Kang
and Han, 2014). Song and colleagues generated podocytes from iPSCs
which, in contrast with their in vivo counterparts, still maintained pro-
liferative capacity, a feature typical of immature cells (Song et al.,
2012). Moreover, in this latter study the efﬁciency and robustness of
the protocol were not discussed. Here, we developed a three-stage pro-
tocol that allowed us to obtain mature podocytes from iPSCs, passing
through a nephron progenitor cell generation step. Our protocol induces
the generation of intermediate mesoderm cells, which then acquire
metanephric mesenchyme cell markers to ﬁnally mature into a
podocyte-lineage cell population.
The expression of T (BRY), taken as amarker of precursors of all me-
sodermal tissues,was here induced through the activation of the canon-
ical Wnt signalling which has been identiﬁed as an inducer for the
primitive streak. A novel GSK3β inhibitor compound, active at a lower
concentration than that reported for the commercially available ana-
logue CHIR99021 (Lam et al., 2014; Mae et al., 2013; Takasato et al.,
2014), was used in combinationwith BMP4 to induce robust generation
of IM cells as soon as 2 days after differentiation. Strong IM commitment
was gained within 3 days of differentiation, as proven by the co-expres-
sion of the speciﬁc IMmarkers OSR1, LHX1 and PAX2. Although expres-
sion of these markers is not unique to kidney development (Fujii et al.,
1994; Puschel et al., 1992), their co-expression in the same cells iden-
tiﬁes a very speciﬁc cell population in the developing kidney. Using a
combination of RA, BMP7 and FGF9, we could direct the maturation of
Fig. 5. Human iPSC-derived podocyte functionality. (A) Representative F-actin immunostaining showed peripheral localization after 24 h of Ang II exposure. Scale bar 50 μm; (B)
percentage of cells showing F-actin rearrangement (*P b 0.05, **P b 0.01). Data are expressed as mean ± s.e.m.; (C) gene expression analysis showed a signiﬁcant reduction in
podocyte marker expression after 3 h of Ang II exposure (*P b 0.05, **P b 0.01). Data are expressed as mean ± s.e.m. (D) representative images of hiPSC-derived podocyte uptake of
FITC-BSA, which accumulated in the perinuclear regions Scale bar 50 μm. (E–F) Integration of human iPSC-derived podocytes into the developing chimeric kidney organoid after
2 days in vitro. (E) iPSC-derived podocytes positive for the human marker human nuclear antigen (HNA, green) were homogeneously distributed within the chimeric organoid among
ureteric bud epithelia positive for E-cadherin (red). (F) 3D reconstruction images showed iPSC-derived podocytes (HNA-positive, green) integrated into WT1-positive (white)
structures (arrows). Inset: HNA-positive cell expressing WT1.
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nephron progenitors of the cap mesenchyme (CM), particularly SIX2,
PAX2 and WT1. During nephrogenesis, the CM cells, when stimulated,
undergo epithelialisation to form podocytes. Studies on zebraﬁsh pro-
nephros formation, a model that mirrors mammalian kidney develop-
ment, have shown that RA actively triggers WT1 expression (Wingert
et al., 2007). RA, by binding to the retinoic acid response elements,mod-
ulates the transcription of numerous genes in stem cells, leading them
to exit the self-renewing state and promoting their differentiation
(Gudas, 2013). In the kidney, the retinoids act on renal progenitors by
promoting their differentiation into mature podocytes. Indeed, RA is a
stronger inducer of WT1 (Bollig et al., 2009), which is a transcription
factor that can physically interact with different co-factors to modulate
the transcriptional activity of essential podocyte genes like podocalyxin
(O'Brien et al., 2011) and nephrin (Guo et al., 2004). In our study, we in-
duced podocyte differentiation by exposing renal progenitor cells to the
VRAD medium, which contains RA. At day 13 of differentiation, cells
showed high expression levels for genes like WT1, SYNPO, NPHS1,
ACTN4, CD2AP, and VEGF-A that have been previously identiﬁed as es-
sential for deﬁning a cell as a podocyte (Shankland et al., 2007). The ex-
pression of the main podocyte markers not only reveals the cellular
identity of the generated cells, but also demonstrates the differentiation
efﬁciency of our protocol, withmore than 90% of the cells co-expressing
WT1 and α-Actinin-4 proteins, and the overall cells expressing
synaptopodin and P-cadherin. Notably, the protocol was stronglyreproducible, generating comparable results across three hiPSC lines
generated with different reprogramming methods (integrative and
non-integrative) and from distinct cell sources (dermal ﬁbroblasts and
PBMCs).
Human podocytes are terminally differentiated cells with the typical
feature of bi- and multinucleated cells, both in vitro and in vivo
(Pavenstadt et al., 2003). Here, iPSC-derived podocytes share the same
characteristics as primary podocytes, as shown by growth arrest and
the presence of a fraction of bi- or multinucleated cells. They acquired
the typical morphology of primary cells with an arborized appearance,
the presence of processes extending from the cell body, and a large cy-
toplasmic to nuclear volume ratio (Shankland et al., 2007). Most impor-
tantly, iPSC-derived podocytes are functional. A recent study from our
group demonstrated that Ang II plays an important role in perpetuating
glomerular injury in experimental and human diabetic nephropathy by
persistently activatingNotch1 and Snail signalling in podocytes, eventu-
ally down-regulating nephrin expression, the integrity of which is cru-
cial for the glomerular ﬁltration barrier (Gagliardini et al., 2013). Ang
II induces actin cytoskeleton rearrangement, which is instrumental to
podocyte permselective dysfunction (Macconi et al., 2006). In our in
vitro model, hiPSC-derived podocytes exposed to Ang II show a rear-
rangement of the cytoskeleton, which is also accompanied by a de-dif-
ferentiation process of the podocytes detected by a marked and
signiﬁcant decrease in the expression of the speciﬁc podocyte markers.
Notably, as previously demonstrated in conditionally immortalized
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from amniotic ﬂuid stem cells (Xinaris et al., 2015), our cells behaved
like functional mature podocytes, able to internalize albumin. Further-
more, iPSC-derived podocytes interacted efﬁciently with mouse renal
progenitors to form ﬁne-grained chimeras, and incorporated abundant-
ly into WT1-positive induced metanephric mesenchyme and develop-
ing glomeruli, conﬁrming their nephrogenic potential.
Compared with other protocols promoting podocyte differentiation
from pluripotent stem cells, our method offers several advantages.
First, the protocol allows podocyte formation in a process reminiscent
of the in vivo kidney developmental stages. Second, hiPSC-derived
podocytes are obtained in only two weeks with high efﬁciency. Lastly,
the hiPSC-derived podocytes share the most important feature of
humanprimary podocytes, not only in terms ofmorphology andmarker
expression, but also as growth behaviour and their ability to respond to
stressors and to internalize albumin.
In conclusion, we have derived functional mature podocytes from
human iPSCs, establishing an efﬁcient differentiation protocol that reca-
pitulates in vivo podocyte development and offers the methodological
basis for exciting investigative approaches. Starting from iPSCs, an inﬁ-
nite source of cells, this protocol will hopefully enable us to better un-
derstand how genetic mutations can affect podocyte development and
physiology. This could involve the introduction in healthy iPSCs of mu-
tations in genes required for renal development, and then monitoring
for a disease phenotype during the developmental stages of our proto-
col. On the contrary, with recent innovations in genome editing, genetic
mutations can be removed from patients' iPSCs and monitored for
healthy phenotype acquisition. Our ﬁndings provide a technical ad-
vance for designing investigations, which make it possible to better de-
ﬁne the molecular and cellular mechanisms of kidney development.
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